ArticleRheumatology international2010
Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.
Article in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2024Pooled it
- Regional risk ofFrontiers in pharmacology · 2023Pooled it
- Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review.Clinical rheumatology · 2020Pooled it
- Prevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Risk of Latent Tuberculosis Infection Reactivation in Patients Treated with Tumor Necrosis Factor Antagonists: A Five-Year Retrospective Study.Tropical medicine and infectious disease · 2025Article
- Retrospective evaluation of active tuberculosis cases in terms of chemoprophylaxis indication: A cross-sectional study.Medicine · 2025Observational
- Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy.African health sciences · 2023Article
- QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.Clinical rheumatology · 2021Article
- Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review.Archives of rheumatology · 2021Review
- Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.Biologics : targets & therapy · 2018Review
- Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.Pediatric rheumatology online journal · 2015Observational
- Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients.Rheumatology international · 2015Observational
- Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.Rheumatology international · 2015Observational
- Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-α agent with a disease-modifying antirheumatic drug?European journal of rheumatology · 2014Article
- Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.Wiener klinische Wochenschrift · 2013Observational
- Authorship problems in scholarly journals: considerations for authors, peer reviewers and editors.Rheumatology international · 2013Article
- Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?Rheumatology international · 2012Article
- Potential role of ustekinumab in the treatment of chronic plaque psoriasis.Biologics : targets & therapy · 2010Article
- Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to estimate the incidence of active tuberculosis in patients with inflammatory diseases receiving tumor necrosis factor-alpha (TNF-alpha) antagonists and to figure out the characteristics of patients who develop tuberculosis. 702 patients with different inflammatory diseases receiving TNF-alpha antagonists were followed up from August 2005 to July 2008 at our department of chest disease. All patients had tuberculin skin test (TST) and postero-anterior chest radiograph (CXR) prior to anti TNF-alpha antagonist treatment. All patients with a TST result > or =5 mm or fibrotic lesions on CXR were administered chemoprophylaxis with isoniazid (INH) for 9 months. 6 (0.85%) patients developed active tuberculosis (4 pulmonary and 2 extrapulmonary) during the follow-up period. TST was found to be positive in 434 (61.8%) of the patients. Patients, who were already on immunosuppressive therapy and who were not, were compared for the difference in their TST results and no statistically significant difference was found. Chemoprophylaxis was administered overall to 583 (83.0%) patients among which 31 (5.3%) developed hepatotoxicity. Of the patients who developed active tuberculosis, all were decided to receive INH chemoprophylaxis, however, only three of them adhered proper treatment. Diagnostic accuracy of TST for detecting latent tuberculosis is high among patients with inflammatory diseases even in the setting of immunosuppression. The risk of development of active TB is increased in this group of patients despite chemoprophylaxis, but this risk remains within the acceptable limits even in a moderate-tuberculosis incidence country, if proper chemoprophylaxis regimen is adhered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.